Press Releases May 19, 2026 04:10 PM

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum

RxSight to Present at Stifel 2026 Virtual Ophthalmology Forum Detailing Innovations in Post-Surgical Vision Customization

By Avery Klein RXST

RxSight, Inc., a NASDAQ-listed ophthalmic medical device company specializing in adjustable intraocular lenses for cataract surgery, announced its participation in the upcoming Stifel 2026 Virtual Ophthalmology Forum. The company’s management will engage in a fireside chat to discuss their Light Adjustable Lens technology and company developments.

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RXST

Key Points

  • RxSight will present at the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026.
  • The company’s Light Adjustable Lens (LAL) is unique as it allows post-surgical adjustments to improve vision outcomes after cataract surgery.
  • The presentation can increase awareness among investors and ophthalmology professionals about RxSight's innovative IOL technology.

ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company’s investor relations website at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
[email protected]


Risks

  • Market adoption risk: The success of the Light Adjustable Lens depends on physician and patient adoption rates within the ophthalmology sector.
  • Regulatory and competitive risks: The medical device industry is subject to regulatory oversight and competition from other IOL providers, which may affect RxSight’s market share.
  • Technological risks: Advances by competitors or technological challenges in the LAL system could affect future sales and company performance.

More from Press Releases

LiqTech International Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Jun 4, 2026 Correction: Keystone Acquisition Corp. Announces Closing of $287.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option Jun 4, 2026 Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026